Wenrui Ouyang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenrui Ouyang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Hongxing Liu
Department of Urology, Guangdong Provincial Key Laboratory of Urological Diseases, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510230, China
4 shared publications Guanlin Li
Department of Urology
2 shared publicationsJuanjuan Li
Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally invasive surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology
2 shared publicationsMengting Wang
Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally invasive surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology
2 shared publications- Sicheng Wu
Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally invasive surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China
2 shared publications - Chao Cai
Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510120, China
1 shared publication
Latest Publications
- 9 May 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (20) , 29392-29406
Light-Responsive Ru–Se Coordinated Nanoreactor Spatiotemporally Relieves Hypoxia for Photodynamic Therapy of Bladder Cancer
Photodynamic therapy (PDT) has been employed as a noninvasive treatment option for bladder cancer due to its controllability and minimal toxicity. However, the efficacy of PDT is often compromised by the hypoxic microenvironment of solid tumors. To address this challenge, our research is dedicated to developing a Ru-Se-Ce6 nanoreactor that combines the photoresponsiveness of Ru-Se coordination bonds and the reactive oxygen species (ROS) triggered by diselenide bonds, achieving dual-controlled release of the photosensitizer to enhance PDT effectiveness. The photoresponsive and catalytic characteristics of the nanoreactor were validated through synchrotron radiation and density functional theory calculations. Under laser irradiation, a metal-to-ligand charge transfer (MLCT) within the ruthenium complex leads to the cleavage of the Ru-Se bond, resulting in the liberation of the ruthenium complex, which significantly improves the O2 generation from H2O2 in the tumor microenvironment (TME). In vivo assessments demonstrated that Ru-Se-Ce6 disrupted the mitochondrial membrane potential via excessive ROS production, leading to cell cycle arrest and apoptosis. Additionally, Ru-Se-Ce6 has revealed significant tumor suppression in subcutaneous and orthotopic bladder tumor models while exhibiting good biocompatibility. These findings propose a potent and innovative approach for bladder cancer therapy.
- 9 May 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (20) , 29392-29406
Light-Responsive Ru–Se Coordinated Nanoreactor Spatiotemporally Relieves Hypoxia for Photodynamic Therapy of Bladder Cancer
Photodynamic therapy (PDT) has been employed as a noninvasive treatment option for bladder cancer due to its controllability and minimal toxicity. However, the efficacy of PDT is often compromised by the hypoxic microenvironment of solid tumors. To address this challenge, our research is dedicated to developing a Ru-Se-Ce6 nanoreactor that combines the photoresponsiveness of Ru-Se coordination bonds and the reactive oxygen species (ROS) triggered by diselenide bonds, achieving dual-controlled release of the photosensitizer to enhance PDT effectiveness. The photoresponsive and catalytic characteristics of the nanoreactor were validated through synchrotron radiation and density functional theory calculations. Under laser irradiation, a metal-to-ligand charge transfer (MLCT) within the ruthenium complex leads to the cleavage of the Ru-Se bond, resulting in the liberation of the ruthenium complex, which significantly improves the O2 generation from H2O2 in the tumor microenvironment (TME). In vivo assessments demonstrated that Ru-Se-Ce6 disrupted the mitochondrial membrane potential via excessive ROS production, leading to cell cycle arrest and apoptosis. Additionally, Ru-Se-Ce6 has revealed significant tumor suppression in subcutaneous and orthotopic bladder tumor models while exhibiting good biocompatibility. These findings propose a potent and innovative approach for bladder cancer therapy.
- 5 December 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 271, 117042
TE-RPA: One-tube telomerase extension recombinase polymerase amplification-based electrochemical biosensor for precise diagnosis of urothelial carcinoma
- 5 December 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 271, 117042
TE-RPA: One-tube telomerase extension recombinase polymerase amplification-based electrochemical biosensor for precise diagnosis of urothelial carcinoma
- Open Access
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 28, 0014
Ferrous Selenide Stabilized Black Phosphorus Heterojunction Sonosensitizer for MR Imaging-Guided Sonodynamic Therapy of Bladder Cancer
It is urgent to develop an alternative dynamic therapy-based method to overcome the limited efficacy of traditional therapy methods for bladder cancer and the damage caused to patients. Sonodynamic therapy (SDT) has the advantages of high tissue penetration, high spatiotemporal selectivity, and being non-invasive, representing an emerging method for eradicating deep solid tumors. However, the effectiveness of SDT is often hindered by the inefficient production of reactive oxygen species and the nondegradability of the sonosensitizer. To improve the anti-tumor effect of SDT on bladder cancer, herein, a BP-based heterojunction sonosensitizer (BFeSe 2 ) was synthesized by anchoring FeSe 2 onto BP via P–Se bonding to enhance the stability and the effect of SDT. As a result, BFeSe 2 showed great cytotoxicity to bladder cancer cells under ultrasound (US) irradiation. BFeSe 2 led to a notable inhibition effect on tumor growth in subcutaneous tumor models and orthotopic tumor models under US irradiation. In addition, BFeSe 2 could also enhance T2-weighted magnetic resonance imaging (MRI) to achieve monitoring and guide treatment of bladder cancer. In general, BFeSe 2 sonosensitizer integrates MRI functions for precise treatment, promising great clinical potential for the theranostics of bladder cancer.
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 28, 0014
Open AccessFerrous Selenide Stabilized Black Phosphorus Heterojunction Sonosensitizer for MR Imaging-Guided Sonodynamic Therapy of Bladder Cancer
It is urgent to develop an alternative dynamic therapy-based method to overcome the limited efficacy of traditional therapy methods for bladder cancer and the damage caused to patients. Sonodynamic therapy (SDT) has the advantages of high tissue penetration, high spatiotemporal selectivity, and being non-invasive, representing an emerging method for eradicating deep solid tumors. However, the effectiveness of SDT is often hindered by the inefficient production of reactive oxygen species and the nondegradability of the sonosensitizer. To improve the anti-tumor effect of SDT on bladder cancer, herein, a BP-based heterojunction sonosensitizer (BFeSe 2 ) was synthesized by anchoring FeSe 2 onto BP via P–Se bonding to enhance the stability and the effect of SDT. As a result, BFeSe 2 showed great cytotoxicity to bladder cancer cells under ultrasound (US) irradiation. BFeSe 2 led to a notable inhibition effect on tumor growth in subcutaneous tumor models and orthotopic tumor models under US irradiation. In addition, BFeSe 2 could also enhance T2-weighted magnetic resonance imaging (MRI) to achieve monitoring and guide treatment of bladder cancer. In general, BFeSe 2 sonosensitizer integrates MRI functions for precise treatment, promising great clinical potential for the theranostics of bladder cancer.